About: NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.02 (+0.99%)
NBP NASDAQ NovaBridge Biosciences
NovaBridge Biosciences share price
Atividade de preço de NBP
Último preço
$ 1,020
Variação (24h)
0,01 USD (0,99%)
Volume
219.60K
Volume (média 4 sem.)
-
Abertura
$ 1,04
Variação do dia
$ 1,02 - $ 1,06
Fechamento anterior
$ 1,01
Último negócio
04 Nov, 8:49 pm GMT+0
Atrasado
04 Nov, 8:49 pm GMT+0
NBP price performance
Atrasado
04 Nov, 8:49 pm GMT+0
NBP details
quote.marketSignals